Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688131.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688131.SS and 80,000+ other tickers.
See exactly how 688131.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688131.SS and 80,000+ other tickers.
Shanghai Haoyuan Chemexpress Co., Ltd. is dedicated to the innovation and advancement of key compounds for the pharmaceutical industry, focusing on small molecule drugs and their essential intermediates. The company's production capabilities encompass active pharmaceutical ingredients (APIs) and their precursors, various vitamin D series substances, as well as specialized chemical building blocks and life science compounds tailored for contract research organizations (CROs). Established in 2006, its primary operational base is located in Shanghai, China.
No recent news available.